See Local News
Get Balanced News From Your U.S. State.
See Local News
See all locals

Ozempic vs Krispy Kreme: Wall Street firm bets weight-loss drugs won’t beat doughnut sales

Posted on AllSides June 11th, 2024
From The Right
Mike Kemp/In Pictures via Getty Images / Getty Images

While the demand for weight loss drugs continues to surge, one Wall Street firm is betting that Americans' love for doughnuts is too strong to give them up. 

Truist Securities on Monday upgraded Krispy Kreme to buy from hold, with analysts led by Bill Chappell saying that the negative impact of the glucagon-like peptide 1 (GLP-1) drugs has already been reflected in the stock's current valuation.

Read full story

AllSides Picks

More News about Banking and Finance from the Left, Center and Right

From the Left

From the Center

From the Right